. Docket No.: SPRX-0023USC1

TN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Confirmation No.: 2992

Mark L. FAUPEL, Shabbir B. BAMBOT, Tim

HARRELL and Anat AGRAWAL

Group Art Unit: 3743

Serial No.: 10/603,597

Examiner: Fadi DAHBOUR

Filed: June 26, 2003

Customer No.: 34610

For: MULTI-MODAL OPTICAL TISSUE DIAGNOSTIC SYSTEM

INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office 220 20th Street S. Customer Window Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202

Sir!

X

Pursuant to 37 C.F.R.§ 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the indicated date. Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, that information cited in the statement is considered to be and/or is material to patentability, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. §120. 1138 OG 37, 38 (May 19, 1992).

- 1. This Information Disclosure Statement is being filed (i) within three months of the U.S. filing date of a U.S. application other than a CPA continued prosecution application under §1.53(d) OR (ii) within three months of the date of entry of the national stage as set forth in §1.491 in an international application OR (iii) before the mailing date of a first Office Action on the merits OR (iv) before the mailing of a first Office Action after the filing of a Request for continued examination under §1.114. No certification or fee is required. 37 C.F.R. §1.97(b).
- 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection OR Notice of Allowance OR an action that otherwise closes prosecution in the application. 37 C.F.R. §1.97(c).
 - a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).



Docket No.: SPRX-0023USC1

		b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).						
		c. Attached is our check noin the amount of \$180.00 in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. 16-0607 as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.						
	3. This Information Disclosure Statement is being filed after the mailing date of a Rejection OR Notice of Allowance OR an action that otherwise closes prosecution is application, but on or before payment of the Issue Fee. Attached is our check no amount of \$180.00 in payment of the fee under 37 C.F.R. §1.17(p). Please credit or Deposit Account No. 16-0607 as needed to ensure consideration of the disclosed informative duplicate copies of this paper are attached. 37 C.F.R. §1.97(d).							
		a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).						
		b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).						
\boxtimes	4.	The reference(s) was/were cited in a corresponding foreign application.						
\boxtimes	includi	To the extent necessary, a petition for an extension of time under 37 C.F.R. §1.136 is made. Please charge any shortage in fees due in connection with the filing of this paper, ng extension of time fees, to Deposit Account 16-0607 and please credit any excess fees a deposit account.						
		FLECHNER & WIM, LDP John C. Eisenhart Registration No. 38 138						
		Registratiøn No. 38,128 Carol L. Druzbick						
~		Registration No. 40,287						

Correspondence Address: P.O. Box 221200 Chantilly, VA 20153-1200 Telephone: (703) 766-3701 Date: October 15, 2004

Please direct all correspondence to Customer Number 34610

LISTOF	·ADT CITE!		DLICANT	ATTY. DOCKET NO. SPRX-0023USC1		APPLN. SERIAL NO. 10/603,597			
LIST OF	ART CITE! (PTO-1	1449)	ILE CLIA	APPLICANT(S) Mark L. FAUPEL, Shabbir B. BAMBOT, Tim HARRELL and Anat AGRAWAL					
			CT 1 5 2004 E	FILING DATE 6/26/2003	GROUP 3743				
U.S. PATENT	DOCUMENTS		& TRADEMA						
EXAMINER'S INITIALS	*PATENT NO.	*ISSUE DATE		NTOR NAME	CLASS	SUBCLASS	FILII DAT		
		US PATE	NT APPLICAT	ION PUBLICATIO	NS	.]			
	*PATENT APPLN. PUB. NO.	*PUB. DATE		PLICANT	CLASS	SUBCLASS			
			U.S. PATENT APP	PLICATIONS					
	*APPLN. *FILING			VENTOR	CLASS	SUBCLASS			
		F	OREIGN PATENT	DOCUMENTS					
EXAMINER'S INITIALS	PATENT NO. WO 99/57529	DATE 11/11/99		DUNTRY	CLASS	SUBCLASS	Transl Yes	ation No	
	WO 98/46133	10/22/98	WIPO						
OTHER A				nt Pages, Publish					
	Fuchs et al., "Combined fluorescene and reflectance spectroscopy: in vivo assessment of oral cavity epithelial neoplasia", Technical Digest. Summaries of Papers Presented at the Conference of Lasers and Electro-Optics. Conference Edition. 1998, Vol 6 (IEEE Cat. No. 98CH36178) pp 306-307, XP002283180 1998, Wash, DC, USA, Opt. Soc. America, USA ISBN: 1-55752-339-0								
EXAMINER			E	ATE CONSIDERE	E D				